Search Results - "Seraphin, Joerg"

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group by Pelzer, Uwe, Schwaner, Ingo, Stieler, Jens, Adler, Mathias, Seraphin, Jörg, Dörken, Bernd, Riess, Hanno, Oettle, Helmut

“…Abstract Background Gemcitabine usually given until progressive disease (PD) is the main first-line treatment option for patients with inoperable advanced…”
Get full text

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial by OETTLE, Helmut, RIESS, Hanno, BISCHOFF, Sven, SINN, Marianne, DÖRKEN, Bernd, PELZER, Uwe, STIELER, Jens M, HEIL, Gerhard, SCHWANER, Ingo, SERAPHIN, Jörg, GÖRNER, Martin, MÖLLE, Matthias, GRETEN, Tim F, LAKNER, Volker

“…To assess the efficacy of a second-line regimen of oxaliplatin and folinic acid-modulated fluorouracil in patients with advanced pancreatic cancer who have…”
Get full text

Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC) by Lorenzen, Sylvie, Knorrenschild, Jorge Riera, Pauligk, Claudia, Hegewisch‐Becker, Susanna, Seraphin, Jörg, Thuss‐Patience, Peter, Kopp, Hans‐Georg, Dechow, Tobias, Vogel, Arndt, Luley, Kim Barbara, Pink, Daniel, Stahl, Michael, Kullmann, Frank, Hebart, Holger, Siveke, Jens, Egger, Matthias, Homann, Nils, Probst, Stephan, Goetze, Thorsten Oliver, Al‐Batran, Salah‐Eddin

“…The RADPAC trial evaluated paclitaxel with everolimus in patients with advanced gastroesophageal cancer (GEC) who have progressed after therapy with a…”
Get full text

Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results by Hofheinz, Ralf, Petersen, Volker, Kindler, Manfred, Schulze, Mathias, Seraphin, Joerg, Hoeffkes, Heinz-Gert, Valdix, Anette-R, Schroeder, Jan, Herrenberger, Julia, Stein, Alexander, Hinke, Axel, Arnold, Dirk

“…To evaluate the efficacy of first-line bevacizumab-based chemotherapy for untreated metastatic colorectal cancer (mCRC) based on age. Eligibility criteria…”
Get full text

Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer by Quidde, Julia, Denne, Laura, Kutscheidt, Andreas, Kindler, Manfred, Kirsch, Andreas, Kripp, Melanie, Petersen, Volker, Schulze, Matthias, Seraphin, Jörg, Tummes, Dirk, Arnold, Dirk, Stein, Alexander

“…In metastatic colorectal cancer, no upfront or on-treatment markers are available to determine the prognosis or efficacy for chemotherapy in combination with…”
Get more information

Prognostic factors for long-term overall survival (OS) for patients (pts) undergoing first-line treatment for metastatic colorectal cancer (mCRC) with chemotherapy (CT) plus bevacizumab (bev): Findings from a large observational study by Arnold, Dirk, Grothe, Wilfried, Tummes, Dirk, Kindler, Manfred, Petersen, Volker, Boszeit-Luft, Stefanie, Seraphin, Joerg, Kutscheidt, Andreas

“…Abstract only 590 Background: Bev+CT has been shown to improve OS vs. CT alone in phase III and IV mCRC studies. However, as only a subset of pts experience OS…”
Get full text

Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study by Hofheinz, Ralf, Grothe, Wilfried, Tummes, Dirk, Kindler, Manfred, Petersen, Volker, Boszeit-Luft, Stefanie, Seraphin, Joerg, Hinke, Axel, Arnold, Dirk

“…Abstract only 566 Background: In most patients (pts) with metastatic colorectal cancer, a 3-drug combination of a fluoropyrimidine, oxaliplatin (ox) or…”
Get full text

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study by Braulke, Friederike, Jung, Klaus, Schanz, Julie, Götze, Katharina, Müller-Thomas, Catharina, Platzbecker, Uwe, Germing, Ulrich, Brümmendorf, Tim H, Bug, Gesine, Ottmann, Oliver, Giagounidis, Aristoteles A.N, Stadler, Michael, Hofmann, Wolf-Karsten, Schafhausen, Philippe, Lübbert, Michael, Schlenk, Richard F, Blau, Igor W, Ganster, Christina, Pfeiffer, Sebastian, Shirneshan, Katayoon, Metz, Michael, Detken, Sven, Seraphin, Jörg, Jentsch-Ullrich, Kathleen, Böhme, Angelika, Schmidt, Burkhard, Trümper, Lorenz, Haase, Detlef

“…Abstract The gold standard of cytogenetic analysis in myelodysplastic syndromes (MDS) is conventional chromosome banding (CCB) analysis of bone marrow (BM)…”
Get full text

Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study by Braulke, Friederike, Schanz, Julie, Metz, Michael, Detken, Sven, Seraphin, Joerg, Götze, Katharina, Mueller-Thomas, Catharina, Platzbecker, Uwe, Brümmendorf, Tim Henrik, Giagounidis, Aristoteles A.N., Germing, Ulrich, Jentsch-Ullrich, Kathleen, Boehme, Angelika, Bug, Gesine, Ottmann, Oliver G., Schafhausen, Philippe, Trümper, Lorenz, Haase, Detlef

“…Abstract 2937 Chromosomal aberrations in myelodysplastic syndromes (MDS) play a major role in diagnostics, pathogenesis, prognosis, and, more recently, in…”
Get full text